Compare Amgen, Inc. (AMGN) vs Figs Inc (FIGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Figs Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Figs Inc trades at $9.78 (market cap $1.68B). The key difference: Amgen, Inc. is far larger — about 116.7× Figs Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Figs Inc pays none. Which is the better fit depends on your goals.
| AMGN | FIGS | |
|---|---|---|
Market Cap | $196.12B | $1.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $17.12 |
52-Week Low | $271.18 | $5.81 |
Enterprise Value | $241.41B | $1.46B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
FIGS trades at $10.04, down 2.81% today, with a bearish technical signal from moving averages despite recent earnings beats. Revenue grew to $631.10M in 2025 with a 66.61% gross margin, but net cash flow remains negative. Analyst consensus is Buy with a $18.00 price target, suggesting significant upside from current levels.
The stock offers growth potential through healthcare apparel demand and global expansion, but faces risks from valuation multiples (P/E 45.64), margin pressures, and persistent negative cash flow. Investor sentiment is mixed amid cost headwinds and competitive dynamics in the apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
